Clinical Trial Update: Neo IRENIE (NEOadjuvant Ipilimumab, RElatlimab, NIvolumab Evaluation) [Phase 2]

View source ↗

Summary

A Phase 2 neoadjuvant trial (Neo IRENIE) evaluating a triple combination of ipilimumab, relatlimab, and nivolumab in resectable cutaneous and mucosal melanoma i…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cutaneous Melanoma
• Mucosal Melanoma

Drugs mentioned

• Relatlimab (relatlimab)
• ipilimumab (ipilimumab)
• nivolumab (nivolumab)

Snippet

Sponsor: Melanoma Institute Australia | Conditions: Cutaneous Melanoma, Mucosal Melanoma | Phase 2 | Status: RECRUITING